Servier agrees to acquire Symphogen
French pharmaceutical company Servier has signed a definitive agreement to acquire 100% shares in Danish therapeutic antibody discovery firm Symphogen....
Focus:
-
XBiotechPartnershipUndisclosed
-
ServierMergers & AcquisitionsUndisclosed
-
GlaxoSmithKlinePartnershipUndisclosed
-
Vir BiotechnologyPartnershipUndisclosed
-
FluGenPartnershipUndisclosed
-
KiteLicensing AgreementUndisclosed
-
AmgenPartnershipUndisclosed
-
Citius PharmaceuticalsLicensing AgreementUndisclosed
-
Aurobindo PharmaMergers & Acquisitions$1BN
-
ImmunityBioPartnershipUndisclosed
-
ExscientiaPartnershipUndisclosed
-
Eli LillyPartnership$880M
-
Cobra BiologicsPartnershipUndisclosed
-
Johnson & JohnsonPartnership$1BN
-
AltimmunePartnershipUndisclosed
-
Dynavax TechnologiesPartnershipUndisclosed
-
Takeda PharmaceuticalPartnership$882M
-
CEPICapital Raising$258M
-
SanofiPartnershipUndisclosed
-
MylanMergers & AcquisitionsUndisclosed
-
GrifolsPartnershipUndisclosed
-
AstraZenecaPartnershipUndisclosed
-
CEL-SCIPartnershipUndisclosed
-
Takeda PharmaceuticalPartnershipUndisclosed
-
BayerLicensing AgreementUndisclosed
-
UniQuestCapital Raising$13M
-
Mitsubishi Tanabe PharmaLicensing AgreementUndisclosed
-
Institut PasteurPartnership$4.9M
-
Ridgeback BiotherapeuticsPartnershipUndisclosed
-
MerckPartnership$47.5M
-
![Vir Biotechnology and Alnylam expand alliance for Covid-19 drugs]()
Vir Biotechnology and Alnylam expand alliance for Covid-19 drugs
-
![FluGen, Bharat Biotech and UW–Madison partner on Covid-19 vaccine]()
FluGen, Bharat Biotech and UW–Madison partner on Covid-19 vaccine
-
![Kite licences Teneobio multiple myeloma targeting antibodies]()
Kite licences Teneobio’s multiple myeloma targeting antibodies
-
![Amgen and Adaptive Biotechnologies to develop Covid-19 drug]()
Amgen and Adaptive Biotechnologies to develop Covid-19 drug
-
![Sandoz; Aurobindo Pharma]()
Novartis terminates $1bn Sandoz US deal with Aurobindo
-
![ImmunityBio and Microsoft Covid-19]()
ImmunityBio and Microsoft create 3D model to support Covid-19 research
Submit a deal
Ensure your company's deals are accurately presented to thousands of potential clients by using our deals submission form.
DEALS ANALYSIS
Covid-19 impact: Global VC funding activity continues to remain subdued
The number of venture capital (VC) funding announced deals dropped by 22.5% during the week ended 29 March 2020 compared to the previous week, according to GlobalData’s deals database.
Healthcare sector witnesses growth in deal activity despite Covid-19 concerns
A total of 152 deals were announced in the global healthcare sector, including pharmaceuticals and medical equipment, during the week ended 29 March 2020 according to GlobalData’s deals database.
Asia-Pacific deal activity drops 18.6% due to coronavirus
A total of 215 deals were announced in the Asia-Pacific (APAC) region during the week ended 29 March 2020, according to GlobalData’s deals database.
Global deal activity decreases 19.7% over coronavirus fears
A total of 837 deals were announced globally during the week ended 29 March 2020, according to GlobalData’s deals database.
Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
Vertex Pharmaceutics has announced it has entered into a definitive agreement to acquire Semma Therapeutics for $950m. Semma is an early-stage biotech that is developing stem cell therapies for type...
Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition
Only eight months after the acceptance of its offer, Japanese pharma company Takeda completed its acquisition of international biotech Shire in January 2019.
US pharma industry sees a drop of 22.2% in deal activity in July 2019
The US pharma industry saw a drop of 22.2% in overall deal activity during July 2019, when compared with the last 12-month average, according to GlobalData's deals database.
Pharma industry deals in July 2019 total $4.57bn globally
Total pharma industry deals for July 2019 worth $4.57bn were announced globally, according to GlobalData's deals database.
Deals interview with Mike Preston of Cleary Gottlieb: Oncology is driving healthcare M&As
Total pharma industry M&A deals in Q2 2019 worth $114.8bn were announced globally, according to GlobalData’s deals database.
China’s pharma industry sees a drop of 28.1% in deal activity in Q2 2019
China's pharma industry saw a drop of 28.1% in overall deal activity during Q2 2019, when compared with the last four-quarter average, according to GlobalData's deals database.
DEALS NEWS
Close
Close
Close
Go Top